Drugs / VMB-100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06247241 | Sep 2025 → Nov 2027 | female stress incontinence | Versameb AG | Withdrawn | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2023-12-12 | Versameb AG | Results Versameb Announces Publication in Molecular Therapy - Nucleic Acids Journal Demonstrating the Potential of Engineered IGF-I mRNA as a Regenerative Therapeutic versameb.com ↗
The paper, entitled ‘Local application of engineered insulin-like growth factor I mRNA demonstrates regenerative therapeutic potential in vivo ’, highlights recent findings, which further demonstrate the therapeutic potential of engineered IGF-I mRNA as a regenerative medicine with a favorable safety profile. |
| 2023-11-16 | Versameb AG | Regulatory Versameb AG Announces FDA Clearance of IND Application for VMB-100 in the Treatment of Stress Urinary Incontinence versameb.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application of VMB-100, a potency enhanced messenger ribonucleic acid (mRNA) encoding human insulin-like growth factor-1 (IGF-1), for the treatment of stress urinary incontinence (SUI). |
| 2022-02-17 | Versameb AG | Results Versameb to present at the Female Pelvic Medicine and Urogenital Reconstruction 2022 Winter Meeting versameb.com ↗
Its lead therapeutic candidate VMB-100 has demonstrated first-in-class potential for treatment for Stress Urinary Incontinence (SUI) in a pre-clinical animal model showing regeneration and functional restoration of the urinary sphincter. |
| 2021-11-04 | Versameb AG | Results Versameb to present novel data on its lead asset, VMB-100 at 9th International mRNA Health Conference versameb.com ↗
VMB-100 has demonstrated first-in-class potential for treatment for Stress Urinary Incontinence (SUI) in a pre-clinical animal model showing regeneration and functional restoration of the urinary sphincter. |
All press releases naming this drug 4 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VMB-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06247241 ↗ |
| Modality | Messenger RNA (mRNA) | “The study drug VMB-100 is an mRNA encoding for IGF-1.” NCT06247241 ↗ |
| Route | Other | “VMB-100 is administered as a transurethral injection into the urinary sphincter muscle.” NCT06247241 ↗ |